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Abstract
In the genomic era of cancer research, the development of metastases has been attributed to mutations in the
tumor that enable the cells to migrate. However, gene analyses revealed that primary tumors and metastases were
in some cases genetically identical and the question was raised whether metastasis formation might be an inher-
ent feature of certain tumor cells. In contradiction to this view, the last decade of cancer research has brought to
light, that tumor cell migration, similar to leukocyte and fibroblast migration, is a highly regulated process. The ner-
vous system plays an important role in this regulation, at least in two respects: firstly, neurotransmitters are known
to regulate the migratory activity of tumor cells, and secondly, nerve fibers are used as routes for perineural inva-
sion. We also summarize here the current knowledge on the innervation of tumors. Such a process might establish
a neuro-neoplastic synapse, with the close interaction of tumor cells and nerve cells supporting metastasis
formation.
Introduction
In January 1971, the US president Richard Nixon intro-
duced in his State of the Union Address the ‘War on
Cancer’ with the aim to find ways to cure cancer within
the next 25 years. Although significant efforts and
advances have been made since then, we are still in a
w a rw i t hc a n c e ra n df a ra w a yf r o mad e f i n i t ev i c t o r y .
With reference to president Nixon’s State of the Union
Address, Michael Sporn published an article in The
Lancet in 1996, in which he reviewed the progress that
was made since 1971, and he pointed out the future
goals of cancer research [1]. One key statement of this
article was: “It is local invasion and distant metastasis
that kill rather than excessive cell proliferation per se.”
In fact today over 90 percent of those patients that die
from their cancer disease do not die due to the primary
tumor but due to the development of metastases. Thus,
there is a pressing need of research on how metastases
occur, and on ways to prevent or treat this ultimate step
in cancer progression.
The end of the previous century was called the geno-
mic era with respect not only to cancer research. Deci-
phering the human genome was probably the most
ambitious project, which actually succeeded in the year
2000 [2]. At this time, genetic models for the develop-
ment of cancer have been established which have deliv-
ered a molecular fundament for the understanding of
processes in cancer cells. One of the earliest and most
famous is the model by Fearon and Vogelstein (1990)
which gives a precise line of genetic events that occur
during the transformation of normal colon epithelium
to a carcinoma [3]. However, this model of colorectal
tumorigenesis does not specify mutations that may con-
stitute the step from carcinoma to metastasis. Since
then a still ongoing debate was raised to what extent
metastasis formation might be genetically determined.
Bernards and Weinberg provided a concept that the ten-
dency to metastasize is acquired early in tumorigenesis
[4]. This assumption is based on observations that pri-
mary tumors are genetically similar or maybe even equal
to their metastases. However, some genes have been
identified that are associated with metastasis formation.
For example, the analysis of the Smad4 gene in colorec-
tal carcinomas showed mutations in 7 percent of the
samples of primary invasive carcinoma without distant
metastasis, but mutations in 35 percent of the samples
of primary invasive carcinoma with distant metastasis
[5]. In 2008, MACC1, a yet largely uncharacterized pro-
tein with putative adaptor function, was also shown to
be a prominent driver of colorectal metastasis [6]. More
recently an amplification of the MTDH gene encoding
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motion of metastasis formation in several types of can-
cer [7].
In addition to this genetically based view there are
several arguments for a non-genetic regulation of metas-
tasis formation. One of the first and most interesting
studies was on the chemokine stromal cell-derived fac-
tor-1 (SDF-1) and its receptor CXCR4. Müller et al.
showed that breast cancer cells express this and other
chemokine receptors [8]. A blockade of CXCR4 resulted
in an impaired metastasis to lymph nodes and lungs in
SCID mice experiments. This result provides evidence
that metastasis formation is not solely genetically based
but regulated by soluble signal substances as well. Mül-
ler et al. drew parallels to the regulation of leukocyte
trafficking, for which the chemokine system is essential.
Tumor cell migration is an essential part of the metas-
tasis cascade, at least in two steps [9]. Firstly, the tumor
cells have to emigrate from the primary tumor and
enter the site of dissemination, either hematogeneous or
lymphogeneous, with the lymphogeneous route dis-
cussed to be a default pathway for tumors incapable of
crossing blood vessel endothelia [10]. Secondly, the
tumor cells have to extravasate form the blood stream
and enter the tissue beyond. In the last years several sig-
nal substances of different classes have been identified
that regulate tumor cell migration. Besides the above
introduced chemokines, cytokines are important regula-
tors, too. For example, the transforming growth factor-b
induces migration in breast carcinoma cells independent
of Smad4, whereas the proliferation of epithelial cells is
mediated by a pathway involving Smad [11]. This shows
with regard to the aforementioned role of Smad4 that
both genetic alterations and non-genetic signalling pro-
cesses can regulate metastasis formation.
Neurotransmitters in metastasis formation
G protein-coupled receptors
Chemokines are well known for their function in leuko-
cyte trafficking and have also been shown to play a role
in tumor cell migration and metastasis development [12].
They bind to receptors of the G protein-coupled receptor
(GPCR) family, an attribute shared with a plethora of
neurotransmitters. It thus seems reasonable to assume
that neurotransmitters could play a role in the regulation
of tumor cell migration or other parts of the metastasis
cascade similar to chemokines. In support of this con-
cept, a number of neurotransmitters have been described
in the last decade to have such a function, with the cate-
cholaminergic system being best characterized.
Catecholamines
Catecholamines are metabolites of the amino acid tyro-
sine, namely dopamine, norepinephrine and epinephrine.
Dopamine is produced in the brain and is released as a
neurohormone with functions in the renal and hormonal
regulation. Dopamine has also been implicated in schizo-
phrenia and Parkinson’s disease [13]. There are only few
reports on the role of dopamine or the according recep-
tors in tumor cell migration and metastasis formation,
for which the following references might be most rele-
vant with regard to this review’s topic [14-16]. In contrast
much more is known about the role of norepinephrine
and epinephrine, the classical stress hormones. The main
source of these neurotransmitters is the adrenal medulla.
Norepinephrine and epinephrine are released in a stress
reaction and cause an increase of the blood pressure,
dilation of airways and glycogenolysis in the liver.
Chronic stress has been implicated in tumor progression
as early as 1926 [17], and several lines of epidemiological
[18,19] and animal studies [20,21] support this view. Nor-
epinephrine induces migratory activity of pancreatic [22],
colonic [23], mammary [15], and prostate carcinoma cells
[24]. With regard to the latter, these results have been
confirmed by a mouse model showing that norepinephr-
ine increases the formation of lymph node metastases by
PC-3 human prostate carcinoma cells [25]. Furthermore,
norepinephrine upregulates the release of vascular
endothelial growth factor (VEGF) and interleukin-6 and
-8 in melanoma cells pointing to a more aggressive
potential of the cells [26]. With regard to the aforemen-
tioned PC-3 human prostate carcinoma cells, an upregu-
lation of the release of interleukin-4 (1.5 ± 0.1 to 2.8 ±
0.1 ng per one million cells; p = 0.006) and of interleu-
kin-8 (9.2 ± 0.8 to 48.9 ± 1.0 ng per one million cells; p <
0.001) was observed in response to norepinephrine,
whereas some further chemokines and cytokines were
released in minor amounts (Fig. 1; Voss and Entschladen,
unpublished data).
Beta-blockers are clinically established drugs that are
used in the treatment of hypertension. Their mechanism
of action is to block beta-adrenergic receptors that are
used by catecholamines to cause their regulatory effects
on the blood pressure. These drugs are of certain inter-
est in oncology, since there exist several lines of evi-
dence that the above described function of
catecholamines in tumor cell migration can be inhibited
by beta-blockers [22,25,27], and beta-blockers might
therefore work as anti-metastatic drugs. Interestingly,
beta-blockers do not only counteract tumor cell migra-
tion and metastasis formation, but also cancer develop-
ment per se; two epidemiological studies show that the
incidence of cancer is reduced in patients that take
beta-blockers [28,29].
Gamma-aminobutyric acid
Gamma-aminobutyric acid (GABA) is a major inhibitory
neurotransmitter of the brain, but has also an important
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pancreatic alpha-cells. This neurotransmitter is dis-
cussed here, because it has been shown that it can
counteract the promigratory effects of catecholamines.
Engagement of GABA receptors inhibits the promigra-
tory norepinephrine effect in pancreatic [30], colonic
[31] and mammary carcinoma [15]. These effects are
mediated by the metabotropic GABAB-receptor, for
which baclofen is a selective agonist that is in clinical
use for the treatment of epilepsy. Furthermore, systemic
administration of baclofen in rats reduced carcinogen-
esis of gastric and colonic cancer [32,33]. Therefore,
GABA-receptor agonists have been suggested to be
introduced into cancer therapy [34].
Inflammatory neurotransmitters
Chronic inflammatory processes can cause cancer, and
conversely cancer can cause inflammatory processes.
Regardless of what accounts for what, inflammation is
clearly implicated in supporting tumor progression [35].
Although it is without doubt that the presence of leuko-
cytes and pro-inflammatory cytokines and chemokines
are the predominant factors for this inflammatory milieu
in tumors [36], one might argue from several observa-
tions on inflammatory neurotransmitters that the ner-
vous system can play a role in tumor progression as well.
Furthermore, as shown in Fig. 1, certain non-inflamma-
tory neurotransmitters can provoke the release of pro-
inflammatory substances such as interleukin-8. However,
histamine, bradykinin, calcitonin gene-related peptide
(CGRP) and substance P are neurotransmitters that are
known to have a direct regulatory function in inflamma-
tory processes. Histamine is released by mast cells, and
an accumulation of these cells around cutaneous tumors
has multiple tumor-progressive effects [37]. Furthermore,
histamine stimulates the migration of cervical carcinoma
[38,39], as well as of epidermoid carcinoma and mela-
noma cells [39]. Bradykinin is a vasoactive nonapeptide,
which has pro-inflammatory function and increases noci-
ception. It has been described to enhance migration in
bladder [40], chondrosarcoma [41] and prostate carci-
noma cells [42]. With regard to the latter, this effect is
specifically mediated by the bradykinin-1 receptor. This
is in so far interesting, as the bradykinin-1 receptor was
only detected in malignant lesions but not in normal
prostate tissue [42]. In contrast to the constitutively
expressed bradykinin-2 receptor, the bradykinin-1 recep-
tor is underrepresented in normal tissue and upregulated
during inflammation [43]. CGRP is abundantly present in
the central nervous system, but also in nerve endings of
peripheral nerves. In these neurons, it is frequently
accompanied by norepinephrine and substance P. CGRP
stimulates the invasive capacity of prostate cancer cell
lines [44], but has no effect on the murine colon adeno-
carcinoma cell line Colon 26-L5 [45].
Substance P has multiple effects as neurotransmitter
and neuro-modulator. It is involved in stress response
and anxiety [46], and related psychological disorders
such as schizophrenia and depression [47]. Furthermore,
substance P plays a role as a modulator of nociception
[48], and has various functions in inflammatory pro-
cesses [49]. For example, it increases the cytokine
release by macrophages under acute stress [50], and the
chemokine production by neutrophil granulocytes [51].
It increases the cytotoxic activity of natural killer cells
and at the same time reduces their migratory activity
[52]. Furthermore, substance P induces migratory activ-
ity in cytotoxic T lymphocytes [52], and reduces the
adhesion of these cells to vascular endothelium [53].
However, substance P plays a role not only as a direct
mediator of inflammation but also communicates
inflammatory processes in peripheral tissue to the brain,
as has been extensively reviewed by Rosenkranz [54].
Very interestingly, in this review Rosenkranz discusses
substance P as a mediator connecting psychological dis-
orders and chronic inflammatory diseases. With regard
to cancer and metastasis formation, substance P causes
an increase of the basal-like human breast carcinoma
cell line MDA-MB-468 [24], and plays a role in the
development of bone marrow metastases in breast can-
cer and neuroblastoma [55]. Furthermore, substance P
has an influence on tumor cell proliferation and angio-
genesis, and therefore a blockade of the relevant recep-
tor, NK-1, has been suggested as a new strategy in the
treatment of cancer [56].
Figure 1 Release of chemokines and cytokines by PC-3 human
prostate carcinoma cells in response to norepinephrine. The
cells were incubated for 12 hours with 10 μM norepinephrine. The
release of the shown substances in the culture medium was
measured using a bead-based multiplex immunoassay and flow-
cytometry according to the manufacturer’s protocol (FlowCytomix,
Bender MedSystems, Vienna, Austria). The graph shows mean values
and standard deviation of three measurements. These are own
unpublished data by Voss and Entschladen.
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How are neurotransmitters delivered to the tumor cells?
Different mechanisms seem possible. Some of the neu-
rotransmitters are systemically disseminated, e.g. the
above discussed catecholamines. But others are only
locally released by nerve endings, thus begging the ques-
tion if tumors are actually innervated. There are cur-
rently only few reports available on this topic. Clinical
observations on tumor innervation have been made con-
cerning esophageal and cardiac carcinoma [57], as well
as prostate cancer [58]. A further argument for tumor
innervation is the fact that tumor cells release sub-
stances which are qualified to cause innervation. Tumor
cells release axon guidance molecules [59], and other
neurotrophic factors which have sometimes an overlap-
ping function in tumor vascularization (neoangiogenesis)
and lymph vessel development (lymphangiogenesis) [60].
For example, the nerve growth factor (NGF) has angio-
genic effects [61,62], and in turn the vascular endothelial
growth factor promotes not only angiogenesis but lym-
phangiogenesis and neurogenesis as well [62-64]. We
thus argue that these three processes - neoangiogenesis,
lymphangiogenesis, innervation - are likely to occur in
concert. These three processes are not sole characteris-
tics of tumors, but occur in any growing tissue in order
to accomplish a proper connection of the new tissue to
supply nourishment and superordinate regulation. How-
ever, sustained angiogenesis is one of the six hallmarks
of cancer [65], and lymphangiogenesis is supposed to be
of similar importance with regard to metastasis forma-
tion [66]. It is thus clear that these two processes sup-
port the growth and progression of a tumor. In contrast,
it is not clear at first glance what kind of support might
arise from tumor innervation, because the neuro-endo-
crine system is a superordinate regulatory system, which
tumors evade. Two points are relevant here. The first
point is, as we have discussed above, that neurotrans-
mitters can increase cell migration and thus support
metastasis formation. Such an interaction can occur in a
neuro-neoplastic synapse which directly provides the
neurotransmitters to the tumor cells [67]. However,
such a synapse has yet only been described in functional
aspects, by the observation of a mutual influence of sig-
nal substances that are released tumor cells and nerve
cells on the respective other cell type as described
herein. There is no morphological characterization so
far. The second point is, that it is well described that
tumor cells use nerve fibers as lines to migrate along, a
phenomenon known as perineural invasion.
Perineural invasion
Perineural invasion has been described for several types
of cancer, as reviewed in [68]. However, the detailed
molecular mechanisms, with which tumor cells interact
with nerve cells are largely unknown. The embryonic
adhesion molecule bystin has been shown to play a role
in prostate cancer [69], and the neural cell adhesion
molecule (N-CAM) is functionally implicated in various
types of cancer, whereas the reports are conflicting with
regard to whether the expression of the N-CAM corre-
lates with perineural invasion or not. N-CAM expres-
sion has been reported in bile duct cancer [70],
squamous cell carcinoma of head and neck [71], pros-
tate cancer [72], and malignancies of the salivary gland
[73]. In summary, although the phenomenon of peri-
neural invasion is well recognized by clinicians in oncol-
ogy since years, much less is known about its
mechanisms in comparison to lymphogenous or hema-
togenous metastasis formation. Nevertheless, there is an
increasing number of publications dealing with this
issue, and perineural invasion may be regarded as a
third way of metastasis formation independent of lymph
or blood vessels [68].
Concluding remarks
Several lines of evidence exist that tumor cells interact
with the nervous system and that they are capable of
responding to its soluble signaling molecules. Different
from its role for normal tissue, the nervous system does
not have the function of a superordinate regulatory organ
for cancer cells, but can still support metastasis in at least
two ways. Firstly, neurotransmitters can directly induce
cell migration or regulate other parts of the metastasic
multi-step process. Secondly, tumor cells can use nerve
fibers as routes for invasion and emigration from the pri-
mary tumors. The latter is of course experimentally diffi-
cult to handle, and there are only few methods
established on this. One of the most advanced methods is
probably that used by Ayala et al., who co-cultured dorsal
root ganglia from mice with tumor cells [74].
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